血浆 microRNA 499 作为急性心肌梗死的生物标志物。

Plasma microRNA 499 as a biomarker of acute myocardial infarction.

机构信息

Department of Cardiology, National Cardiovascular Center, Suita, Osaka, Japan.

出版信息

Clin Chem. 2010 Jul;56(7):1183-5. doi: 10.1373/clinchem.2010.144121. Epub 2010 Apr 15.

DOI:10.1373/clinchem.2010.144121

PMID:20395621

Abstract

BACKGROUND

MicroRNAs (miRNAs) are endogenous small RNAs 21-25 nucleotides in length. Recently, we reported that miRNA 208 (miR-208) is produced exclusively in the rat myocardium and that plasma miR-208 is a biomarker of myocardial injury in rats. In the present study, we assessed the hypothesis that plasma concentrations of myocardial-specific miRNAs can be used to diagnose myocardial injury in humans.

METHODS

We used array analysis of miRNA production in various human tissues to identify heart-specific miRNAs. We assessed the plasma concentrations of miR-499 in 14 individuals with acute coronary syndromes, 15 individuals with congestive heart failure, and 10 individuals without cardiovascular diseases. Plasma miR-499 concentrations were measured with a real-time reverse-transcription PCR method that used an artificial small RNA as an internal calibrator.

RESULTS

The miRNA array analysis of various human tissues indicated that miR-499 was produced almost exclusively in the heart. Plasma miR-499 concentrations were measurably increased in all individuals with acute myocardial infarction but were below the limit of detection for all individuals in the other patient groups.

CONCLUSIONS

The plasma concentration of miR-499 may be a useful biomarker of myocardial infarction in humans.

摘要

背景

MicroRNAs（miRNAs）是长度为 21-25 个核苷酸的内源性小 RNA。最近，我们报道了 miRNA 208（miR-208）仅在大鼠心肌中产生，并且血浆 miR-208 是大鼠心肌损伤的生物标志物。在本研究中，我们评估了以下假设，即心肌特异性 miRNAs 的血浆浓度可用于诊断人类心肌损伤。

方法

我们使用 miRNA 产生的阵列分析来鉴定各种人类组织中的心脏特异性 miRNAs。我们评估了 14 名急性冠状动脉综合征患者、15 名充血性心力衰竭患者和 10 名无心血管疾病患者的血浆 miR-499 浓度。使用实时逆转录 PCR 方法测量血浆 miR-499 浓度，该方法使用人工小 RNA 作为内部校准物。